{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:17:12Z","timestamp":1784593032905,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajem.2025.08.067","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:08:21Z","timestamp":1756768101000},"page":"283-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["High risk and low incidence diseases: Tumor lysis syndrome"],"prefix":"10.1016","volume":"98","author":[{"given":"Kevin","family":"Molyneux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beck-Esmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Koyfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2025.08.067_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OAEM.S73684","article-title":"Tumor lysis syndrome in the emergency department: challenges and solutions","volume":"7","author":"Namendys-Silva","year":"2015","journal-title":"Open Access Emerg Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: New therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.ajem.2025.08.067_bb0015","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajem.2025.08.067_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5492\/wjccm.v4.i2.130","article-title":"Tumor lysis syndrome: a clinical review","volume":"4","author":"Mirrakhimov","year":"2015","journal-title":"World J Crit Care Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/hon.2668","article-title":"Current understanding of tumor lysis syndrome","volume":"37","author":"Rahmani","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajem.2025.08.067_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.07.005","article-title":"Myocardial calcification in a patient with B-lymphoblastic leukemia accompanied by tumor lysis syndrome","volume":"43","author":"Usui","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.transci.2008.11.004","article-title":"The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF)","volume":"41","author":"Nakamura","year":"2009","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ajem.2025.08.067_bb0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.emc.2018.04.003","article-title":"Rapid fire: tumor lysis syndrome","volume":"36","author":"Dubbs","year":"2018","journal-title":"Emerg Clin N Am"},{"key":"10.1016\/j.ajem.2025.08.067_bb0050","article-title":"Immune checkpoint inhibitor-associated tumor lysis syndrome: a real-world pharmacovigilance study","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ajem.2025.08.067_bb0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3810\/pgm.2012.03.2540","article-title":"Tumor lysis syndrome: a systematic review of case series and case reports","volume":"142","author":"Firwana","year":"2012","journal-title":"Postgrad Med J"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0060","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0002-9343(84)90550-3","article-title":"Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon","volume":"77","author":"Fer","year":"1984","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0065","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2214\/AJR.04.1265","article-title":"Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma","volume":"185","author":"Lehner","year":"2004","journal-title":"AJR"},{"key":"10.1016\/j.ajem.2025.08.067_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CLEP.S454263","volume":"16","author":"Choi","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3350\/cmh.2015.21.1.85","article-title":"Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.ajem.2025.08.067_bb0080","article-title":"Steroid-induced tumor lysis syndrome accompanied by diabetic ketoacidosis and acute renal failure in a non-Hodgkin lymphoma patient","volume":"14","author":"Cao","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40792-024-01901-1","article-title":"Tumor lysis syndrome following letrozole for locally advanced breast cancer: a case report","volume":"10","author":"Kikuchi","year":"2024","journal-title":"Surg Case Rep"},{"issue":"4","key":"10.1016\/j.ajem.2025.08.067_bb0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198607243150417","article-title":"Tumor lysis syndrome after tamoxifen flare","volume":"315","author":"Cech","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5858\/arpa.2017-0278-RS","article-title":"Tumor lysis syndrome","volume":"143","author":"Williams","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241274909","article-title":"Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA adverse event reporting system database","volume":"15","author":"Li","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ajem.2025.08.067_bb0105","article-title":"Tumor lysis syndrome in a patient with metastatic endometrial Cancer treated with lattice stereotactic body radiation therapy","volume":"7","author":"Schiff","year":"2021","journal-title":"ARO"},{"key":"10.1016\/j.ajem.2025.08.067_bb0110","first-page":"24","article-title":"Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: a case report and review of the literature","volume":"32","author":"Cailleteau","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ajem.2025.08.067_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12691\/ajmcr-7-7-4","article-title":"Tumor lysis syndrome after hepatic artery embolization in a patient with neuroendocrine tumor of unknown primary","volume":"7","author":"Barrett-Campbell","year":"2019","journal-title":"Am J Med Case Rep"},{"key":"10.1016\/j.ajem.2025.08.067_bb0120","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13256-024-04928-y","article-title":"Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report","volume":"18","author":"Li","year":"2024","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.ajem.2025.08.067_bb0125","article-title":"Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed\/refractory multiple myeloma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"31","key":"10.1016\/j.ajem.2025.08.067_bb0130","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2007.14.2141","article-title":"Tumor lysis syndrome\/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia","volume":"25","author":"Moutouh-de Parseval","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.11-1-87","article-title":"Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma","volume":"11","author":"Lee","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ajem.2025.08.067_bb0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.10220","article-title":"Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera","volume":"71","author":"Ellis","year":"2002","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0145","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1345\/aph.1C188","article-title":"Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia","volume":"37","author":"Seki","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ajem.2025.08.067_bb0150","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1634\/theoncologist.2017-0147","article-title":"In-hospital outcomes of tumor lysis syndrome: a population-based study using the National Inpatient Sample","volume":"22","author":"Durani","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0155","article-title":"Outcomes of tumor lysis syndrome in hospitalized patients: a retrospective cohort Study from National Inpatient Sample 2016-2019","volume":"140","author":"Ghimire","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ajem.2025.08.067_bb0160","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-8-2","article-title":"Tumor lysis syndrome in childhood malignancies","volume":"9","author":"Cheung","year":"2020","journal-title":"Drugs Context"},{"issue":"21","key":"10.1016\/j.ajem.2025.08.067_bb0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V120.21.238.238","article-title":"Incidence of treatment-related, laboratory and clinical tumor lysis syndrome","volume":"120","author":"Cairo","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.ajem.2025.08.067_bb0170","first-page":"3390","article-title":"Recent trends in the incidence and outcomes of tumor lysis syndrome in hematological malignancies: data from 2010-2014 national inpatient sample","volume":"130","author":"Pathak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ajem.2025.08.067_bb0175","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9684909","article-title":"Tumor lysis syndrome in patients with hematological malignancies","volume":"2017","author":"Belay","year":"2017","journal-title":"J Oncol"},{"issue":"2","key":"10.1016\/j.ajem.2025.08.067_bb0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190903456959","article-title":"Prognostic significance of acute renal injury in acute tumor lysis syndrome","volume":"51","author":"Darmon","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/joa3.12482","article-title":"Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: a nationwide inpatient analysis","volume":"37","author":"Gangani","year":"2020","journal-title":"Int J Arrhythm"},{"issue":"10","key":"10.1016\/j.ajem.2025.08.067_bb0190","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03150312","article-title":"Onco-nephrology: Tumor lysis syndrome","volume":"7","author":"Wilson","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajem.2025.08.067_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1525-139X.2009.00575.x","article-title":"The general picture of uremia","volume":"22","author":"Almeras","year":"2009","journal-title":"Semin Dial"},{"issue":"6","key":"10.1016\/j.ajem.2025.08.067_bb0200","article-title":"Intractable hiccups in a patient with end-stage renal disease: a five-month ordeal resolved through hemodialysis","volume":"16","author":"Minoretti","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ajem.2025.08.067_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2023.08.044","article-title":"A case of spontaneous tumor lysis syndrome in an adolescent with abdominal pain","volume":"73","author":"Osborne","year":"2023","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.2830160211","article-title":"Tumor lysis syndrome following VP-16-213 in chronic myeloid leukemia in blast crisis","volume":"16","author":"Thomas","year":"1984","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.12659\/AJCR.915351","article-title":"A case report of Atezolizumab induced tumor lysis syndrome","volume":"20","author":"Fa\u2019ak","year":"2019","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ajem.2025.08.067_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2022.107518","article-title":"Advanced ovarian cancer that resulted in death from intestinal perforation following tumor lysis syndrome: a case report","volume":"98","author":"Kunimoto","year":"2022","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.ajem.2025.08.067_bb0225","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.emc.2025.04.002","article-title":"Tumor lysis syndrome","volume":"43","author":"Lindsay","year":"2025","journal-title":"Emerg Med Clin N Am"},{"issue":"11","key":"10.1016\/j.ajem.2025.08.067_bb0230","article-title":"Images in clinical medicine Chvostek\u2019s and Trousseau\u2019s signs [published correction appears in N Engl J Med. 2012 Dec 6;367(23):2262]","volume":"367","author":"Jesus","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ajem.2025.08.067_bb0235","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102603","article-title":"Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel","volume":"120","author":"Perissinotti","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ajem.2025.08.067_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119497","article-title":"Uric acid and the prediction models of tumor lysis syndrome in AML","volume":"10","author":"Ejaz","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ajem.2025.08.067_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/17474086.2016.1127156","article-title":"Tumor lysis syndrome: review of pathogenesis, risk factors, and management of a medical emergency","volume":"9","author":"Criscuolo","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6977","article-title":"Burkitt lymphoma presenting as cecum mass and spontaneous tumor lysis syndrome with hypercalcemia","volume":"11","author":"Shafie","year":"2023","journal-title":"Clin Case Reports"},{"issue":"10","key":"10.1016\/j.ajem.2025.08.067_bb0265","article-title":"Spontaneous tumour lysis syndrome in mantle cell lymphoma: a case study","volume":"14","author":"Taha","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0270","article-title":"Spontaneous tumor lysis syndrome in diffuse large B-cell lymphoma: early diagnosis and management","volume":"11","author":"Gangireddy","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.ajem.2025.08.067_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1337295","article-title":"Prediction of tumor lysis syndrome in childhood acute lymphoblastic leukemia based on machine learning models: a retrospective study","volume":"14","author":"Xiao","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ajem.2025.08.067_bb0280","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ajem.2025.08.067_bb0285","article-title":"Tumor lysis syndrome in patients with solid tumors: a systematic review of reported cases","volume":"14","author":"Alqurashi","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0290","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1053\/j.ackd.2021.09.007","article-title":"Tumor lysis syndrome","volume":"28","author":"Barbar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1016\/j.ajem.2025.08.067_bb0295","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/20009666.2020.1761185","article-title":"Diagnosis and management of tumor lysis syndrome","volume":"10","author":"Puri","year":"2020","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"9","key":"10.1016\/j.ajem.2025.08.067_bb0300","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1711584","article-title":"Balanced crystalloids versus saline in critically ill adults","volume":"378","author":"Semler","year":"2018","journal-title":"NEJM"},{"issue":"27","key":"10.1016\/j.ajem.2025.08.067_bb0305","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of Rasburicase alone and Rasburicase followed by allopurinol compared with allopurinol alone\u2014results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.ajem.2025.08.067_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006945.pub2","article-title":"Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer","volume":"6","author":"Cheuk","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.ajem.2025.08.067_bb0320","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/blood.V126.23.4511.4511","article-title":"A comparison of single dose Rasburicase 3 Mg versus 6 Mg for the management of tumor lysis syndrome","volume":"126","author":"Kraus","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0325","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jcpt.12479","article-title":"The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis","volume":"42","author":"Yu","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0330","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jemermed.2019.03.043","article-title":"Management of Hyperkalemia with insulin and glucose: pearls for the emergency clinician","volume":"57","author":"Moussavi","year":"2019","journal-title":"J Emerg Med"},{"issue":"2","key":"10.1016\/j.ajem.2025.08.067_bb0335","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jemermed.2018.04.004","article-title":"Controversies in Management of Hyperkalemia","volume":"55","author":"Long","year":"2018","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajem.2021.11.030","article-title":"Dispelling myths and misconceptions about the treatment of acute hyperkalemia","volume":"52","author":"Gupta","year":"2022","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2025.08.067_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.resuscitation.2025.110489","article-title":"Pharmacological interventions for the acute treatment of hyperkalaemia: a systematic review and meta-analysis","volume":"208","author":"Jessen","year":"2025","journal-title":"Resuscitation"},{"key":"10.1016\/j.ajem.2025.08.067_bb0350","series-title":"American College of Emergency Physicians","year":"2021"},{"key":"10.1016\/j.ajem.2025.08.067_bb0355","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1159\/000509934","article-title":"Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress","volume":"45","author":"Matuszkiewicz-Rowinska","year":"2020","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0360","article-title":"A retrospective single-center study of Sevelamer hydrochloride for the treatment of hyperphosphatemia in children with tumor lysis syndrome","volume":"15","author":"Al Blewi","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ajem.2025.08.067_bb0365","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/biomedicines10051012","article-title":"Tumor lysis syndrome: an endless challenge in onco-nephrology","volume":"10","author":"Lupusoru","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ajem.2025.08.067_bb0370","first-page":"50","article-title":"Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach","volume":"17","author":"Hsu","year":"2004","journal-title":"J Nephrol"},{"key":"10.1016\/j.ajem.2025.08.067_bb0375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00467-006-0287-z","article-title":"Acute renal failure from xanthine nephropathy during management of acute leukemia","volume":"22","author":"LaRosa","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.ajem.2025.08.067_bb0380","first-page":"525","article-title":"Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis","volume":"44","author":"Bellos","year":"2019","journal-title":"J Clin Pharm Ther"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675725006035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675725006035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:22:08Z","timestamp":1768429328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675725006035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":76,"alternative-id":["S0735675725006035"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2025.08.067","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High risk and low incidence diseases: Tumor lysis syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2025.08.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}